# **Summary of Product Characteristics**

## **1 NAME OF THE MEDICINAL PRODUCT**

Dymista 137 micrograms / 50 micrograms per actuation, Nasal Spray Suspension

#### **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each g of suspension contains 1000 micrograms azelastine hydrochloride and 365 micrograms fluticasone propionate.

One actuation (0.14 g) delivers 137 micrograms azelastine hydrochloride (= 125 micrograms azelastine) and 50 micrograms fluticasone propionate.

Excipient(s) with known effect: This medicinal product contain benzalkonium chloride.

For the full list of excipients, see section 6.1.

#### **3 PHARMACEUTICAL FORM**

Nasal spray, suspension.

Product imported from Greece.

White, homogenous suspension

#### **4 CLINICAL PARTICULARS**

As per PA23355/010/001

#### **5 PHARMACOLOGICAL PROPERTIES**

As per PA23355/010/001

#### **6 PHARMACEUTICAL PARTICULARS**

#### 6.1 List of excipients

Disodium edetate Glycerol Microcrystalline cellulose Carmellose sodium Polysorbate 80 Benzalkonium chloride Phenylethyl alcohol Purified water

#### 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

The shelf-life expiry date of this product shall be the date shown on the container and outer package of the product on the market in the country of origin. In-use shelf life (after first use): 6 months.

## 6.4 Special precautions for storage

Do not refrigerate or freeze.

## 6.5 Nature and contents of container

Amber glass bottle fitted with a spray pump, a nasal applicator (actuator) and a dust cap, containing 23 g (at least 120 actuations) suspension. Pack size: 1 bottle with 23 g suspension in 25 ml bottle (at least 120 actuations).

## 6.6 Special precautions for disposal and other handling

No special requirements for disposal.

## 7 PARALLEL PRODUCT AUTHORISATION HOLDER

Merit Pharmaceuticals Limited Unit C4/C3 Metropoint Business Park Kettles Lane Swords Co Dublin K67 RH92 Ireland

### **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA23080/018/001

## 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 9<sup>th</sup> February 2018

#### **10 DATE OF REVISION OF THE TEXT**

November 2024